Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bastian Jaeschke

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|November 20, 2019
Neoadjuvant therapy with vemurafenib in Horner's syndrome as a very rare first diagnosis of a malignant melanoma of unknown primaryKonstanze Gebauer, Joachim Schirren, Bastian Jaeschke, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 28, 2020
Konstanze Gebauer, Joachim Schirren, Bastian Jaeschke, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 1, 2026
Fibroblast Activation Protein-Targeted Radiopharmaceutical Therapy Using <sup>177</sup>Lu-, <sup>90</sup>Y-, and <sup>225</sup>Ac-Labeled 3BP-3940: First Experience in 21 Different Advanced MalignanciesRichard P Baum, Tianzhi Zhao, Vivianne Jakobsson, et al.
Seminars in Nuclear Medicine|July 17, 2024
Radiomolecular Theranostics With Fibroblast-Activation-Protein Inhibitors and PeptidesRichard P Baum, Emil Novruzov, Tianzhi Zhao, et al.
JTO Clinical and Research Reports|April 8, 2024
Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)Frank Griesinger, Martin Sebastian, Wolfgang M Brueckl, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|November 20, 2019
Neoadjuvant therapy with vemurafenib in Horner's syndrome as a very rare first diagnosis of a malignant melanoma of unknown primaryKonstanze Gebauer, Joachim Schirren, Bastian Jaeschke, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 28, 2020
Konstanze Gebauer, Joachim Schirren, Bastian Jaeschke, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 1, 2026
Fibroblast Activation Protein-Targeted Radiopharmaceutical Therapy Using <sup>177</sup>Lu-, <sup>90</sup>Y-, and <sup>225</sup>Ac-Labeled 3BP-3940: First Experience in 21 Different Advanced MalignanciesRichard P Baum, Tianzhi Zhao, Vivianne Jakobsson, et al.
Seminars in Nuclear Medicine|July 17, 2024
Radiomolecular Theranostics With Fibroblast-Activation-Protein Inhibitors and PeptidesRichard P Baum, Emil Novruzov, Tianzhi Zhao, et al.
JTO Clinical and Research Reports|April 8, 2024
Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)Frank Griesinger, Martin Sebastian, Wolfgang M Brueckl, et al.
Pageof 1